AI Sample-Size Reduction Has a Methodology; the Validation Infrastructure Is Missing

Since the June 1 issue flagged FDA’s AI Early-Phase Pilot RFI and the ~20% external-performance-overestimation finding, the landscape has sharpened in one important direction: a preprint on arXiv (2605.23246) has now made the methodology explicit. It proposes using AI-derived prognostic covariates to prospectively reduce planned sample sizes in registrational RCTs, walks through all seven steps of FDA’s draft risk-based AI credibility framework, and demonstrates the approach in an Alzheimer’s Disease example. This is no longer a theoretical possibility — it is a documented, step-by-step proposal with a named regulatory pathway.

The core statistical mechanism is covariate adjustment: an AI model generates prognostic scores that, incorporated into the primary analysis model, reduce residual variance and allow smaller samples to achieve the same power. This is methodologically adjacent to well-established ANCOVA practice, and FDA’s 2023 covariate adjustment guidance already permits ML-based adjustment when pre-specified. A companion Clinical Trials paper on ML-optimized covariate adjustment in the SEARCH HIV trial provides a worked confirmatory-trial example of exactly this “pre-specified, yet data-adaptive” approach — useful evidence that the framework can survive contact with real data.

The ASA BIOP commentary is where the methodological optimism meets its counterweight. Across 13 passively collected clinical datasets, medical AI models relying on hidden data-acquisition biases overestimated external performance by roughly 20% on average. The disciplinary point is precise: AI detects patterns; statistics determines when they constitute evidence of a treatment effect. Showing that a model is internally predictive is not sufficient — sponsors need to demonstrate that learned representations encode causally relevant structure, not scanner settings or local documentation habits.

This is the validation asymmetry that defines the current moment. The arXiv preprint, the ML covariate-adjustment paper, and Veristat’s InStat platform — which uses AI agents for specification drafting but deliberately routes regulatory outputs through pre-validated statistical engines — all accept a high evidentiary bar and engineer around the risk. The LLM layer being inserted upstream in SAP authoring has not yet been held to the same standard. Derek Lowe’s coverage of a study in which accuracy degraded across six LLMs simply by swapping “Reassurance” for “None of the above” captures the problem efficiently: prompt sensitivity of that kind is a structural property of the technology, not a quirk to be managed.

Regulators are still in framework-building mode. FDA has extended its Early-Phase AI Pilot RFI comment period to June 29 (Docket FDA-2026-N-4390) — the public docket will be worth pulling after that deadline for a read on where major sponsors and CROs are positioning themselves. EMA’s first AI Observatory annual report (EMA/76534/2025) covers the network’s own 2024 AI experience; whether the agency applies the same validation standards to its internal tools as it asks of sponsors is a question worth tracking.

The practical read for biometrics teams: the methodology for AI-assisted sample size reduction in registrational trials now exists and maps to existing FDA guidance. The validation infrastructure to support it credibly — across model development, external qualification, prospective lock, and data-provenance documentation — does not yet exist at scale. Building that infrastructure before the first submission attempt is not a compliance formality; it is the work.

Protocol read: The methodology for AI-assisted sample size reduction is no longer speculative; the validation infrastructure to support it credibly at submission still is. Building that infrastructure prospectively, before the first registrational use, is the work — not a compliance formality.

What to do now:

• For any AI-prognostic-covariate sample size reduction proposal, build the seven-step credibility documentation prospectively — locked model, external qualification, data-provenance trail — before the SAP is finalized.
• Pull the FDA AI Pilot RFI public docket after June 29 to read where major sponsors are positioning on validation expectations.
• Treat LLM-mediated SAP authoring with the same validation rigor as the downstream inference layer; prompt sensitivity is a structural property of the technology, not a quirk to be managed.